Objectives: To identify the pharmacokinetic/pharmacodynamic parameters and exposures of linezolid in the treatment of pulmonary Mycobacterium avium complex (MAC) disease.
Introduction
Mycobacterium avium complex (MAC), which includes Mycobacterium avium and Mycobacterium intracellulare, causes chronic pulmonary infection in otherwise immunocompetent individuals. Current treatment guidelines recommend the use of macrolides and ethambutol along with rifamycins. 1 However, the sputum conversion rates (defined as at least two negative sputum smears or cultures) with the current treatment regimen were found in our meta-analysis to be 42% at the end of therapy and 22% in patients treated beyond a year. 2 Thus, the available clinical evidence indicates that current treatment regimens for pulmonary MAC disease are frequently ineffective. In addition, because of the poor kill rates of MAC by ethambutol and macrolides, the treatment duration is at least 12 months and may even take several years. 1, 3, 4 Therefore, there is an urgent need to investigate new antibiotics that could be more efficacious, and to establish new regimens.
In one study of adult patients undergoing diagnostic bronchoscopy who received the standard dose of the oxazolidinone linezolid, mean concentrations were 13.4 mg/L in serum, 8 .1 mg/L in alveolar macrophages and 25.1 mg/L in epithelial lining fluid (ELF), with mean site/serum concentration ratios of 0.79 for bronchial mucosa, 0.71 for macrophages and 8.35 for ELF, indicating good lung penetration. 5 In another study, designed to calculate the 0-24 h area under the concentration-time curve (AUC 0-24 ) ELF-toserum ratio, Conte et al. 6 identified a penetration ratio of 3.29. In a recent study of intracellular tuberculosis (TB), we observed that linezolid was concentrated inside infected macrophages and achieved an AUC 0-24 that was 3-fold the extracellular concentrations, indicating good penetration. 7 The high intracellular and intrapulmonary concentrations suggest that linezolid could have pharmacokinetic advantages in the treatment of pulmonary MAC, an intracellular disease. Moreover, linezolid has shown good antimycobacterial activity. In a recent randomized trial of patients with extensively drug-resistant TB who received linezolid in addition to a failing regimen, 89% achieved sputum culture conversion by 6 months. 8 In addition, linezolid is available as an oral formulation and has good bioavailability with relatively low protein binding. 9 These properties make linezolid an obvious candidate that has potential to treat pulmonary MAC. Here, we used our hollow-fibre system model of MAC (HFS-MAC) to mimic human ii24 J Antimicrob Chemother 2017; 72 Suppl 2: ii24-ii29 doi:10.1093/jac/dkx304 concentration-time profiles achieved in the lung in a pharmacokinetic/pharmacodynamic (PK/PD) study to identify optimal exposures of linezolid that could help design treatment for pulmonary MAC disease.
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Materials and methods
Bacteria and chemicals
M. avium Chester (ATCC 700898) was utilized for the HFS-MAC experiments. Stock cultures were stored in Middlebrook 7H9 broth and 10% glycerol at # 80 C. Before each experiment bacterial stock was thawed and incubated in a water bath in Middlebrook 7H9 broth with 10% OADC at 37 C for 72-96 h under shaking conditions in order to achieve logarithmic-phase growth. Linezolid intravenous formulation was purchased from the Baylor University Medical Center pharmacy. Linezolid was shielded from direct light in all experiments. Hollow-fibre cartridges were purchased from FiberCell (Frederick, MD, USA).
Determination of MIC
Linezolid MIC was determined using broth macrodilution. The turbidity of MAC culture in exponential-phase growth was adjusted using optical density and then diluted to achieve a bacterial density of 1.5%10 6 cfu/mL, and co-incubated with linezolid concentrations of 0, 0.5, 1.0, 1.25, 1.5, 2.0, 2.5, 3.0, 4.0, 8.0 and 16 mg/L in conical tubes containing Middlebrook 7H9 broth in triplicate. On day 7, cultures were washed twice with normal saline to remove carried-over drug and then serially diluted and cultured on Middlebrook 7H10 agar supplemented with 10% OADC (hereafter termed 'agar'). Cultures were incubated at 37 C. Colony counts were performed 14 days later. The lowest concentration that prevented at least 99% of the growth observed in the absence of linezolid was defined as the MIC. This experiment was performed twice.
Infection of THP-1 cells with MAC
Human-derived THP-1 monocytes (ATCC TIB-202) were cultured in pre-warmed RPMI 1640 with 10% FBS (RPMI/FBS). THP-1 cells were co-incubated overnight with MAC at a bacterium-to-macrophage ratio of 1:1. The infected macrophages were then centrifuged at 200 g for 5 min to wash off extracellular bacteria, following which cells were counted using a haemocytometer. A sample of THP-1 cells was then ruptured to determine the cfu/mL, as described below.
Exposure effect study of intracellular MAC THP-1 monocytes at a density of 1.5%10 6 cells/mL were activated using phorbol myristate acetate (PMA) at a final concentration of 10 nM in 12-well plates, starting 72 h prior to infection. The activated cells were then infected as described above, and the adherent cells washed twice in warm RPMI/FBS, and then co-incubated with linezolid concentrations of 0, 0.15, 0.3, 0.6, 1.25, 2.5 and 5.0 mg/L for 14 days in triplicate. On day 14, the adherent cells were washed twice in warm RPMI 1640 and then lysed with PBS containing 0.025% Tween-20 (PBS-T). The cultures were then serially diluted, and cultured on agar at 37 C under 5% CO 2 for 14 days for colony counts.
Exposure-response and dose-scheduling study in the hollow-fibre system
The HFS-MAC model and its construction have been described in detail previously. 3, 10, 11 We injected 20 mL of non-activated MAC-infected THP-1 cells into the external compartment of each of 16 HFS-MAC units preconditioned with RPMI/FBS and maintained them in incubators at 37 C under 5% CO 2 for at least 72 h. We mimicked human lung concentration-time profiles of linezolid as demonstrated in several studies, which have identified a half-life from 3.5-8.4 h. 5, 6, 12, 13 Linezolid was delivered by computerprogrammed syringe pumps into the central compartment. Nine of the 15 HFS were dosed with linezolid once daily to achieve AUC 0-24 s of 0, 3.5, 7, 26.4, 52.8, 76, 90, 105 and 180 mgÁh/L as part of the dose-effect study. Based on the results of the 12-well plate studies above, two other HFS-MAC units were dosed with linezolid twice a day to achieve AUC 0-24 exposures of 105 and 180 mgÁh/L (and therefore half the peak concentrations of the corresponding once-daily doses), and the remaining four HFS-MAC systems were treated with linezolid every 48 h to achieve 48 h AUC exposures double those of 7, 26.4, 90 and 105 mgÁh/L (and thus same AUC 0-24 but double the peak). This dose fractionation exercise was to break the co-linearity of the AUC 0-24 /MIC ratio with the peak concentration-to-MIC ratio (C max /MIC), and the proportion of time for which the concentration exceeds the MIC (fT .MIC ). The duration of therapy was 28 days. In order to validate the concentration-time profiles of linezolid achieved in the HFS-MAC, sampling of the central compartment of each system was performed at seven timepoints over a 24 h period after drug infusion based on optimal sampling theory. Linezolid concentration assay was as described by us previously. 7 The peripheral compartments were also sampled on day 0, 3, 5, 7, 10, 14, 18, 21 and 28 for quantification of the MAC burden and THP-1 cell counts. THP-1 cells were counted in a Coulter counter as well as manually after trypan blue staining for cell viability. Bacterial samples were cultured on agar as described above.
Pharmacokinetic and PK/PD modelling
Pharmacokinetic analysis was performed in ADAPT 5, following steps specified previously. 3, 10, 11 The best multicompartment model was chosen using the Akaike Information Criterion (AIC) score. The AUC 0-24 and fT .MIC were calculated from the ADAPT 5 output. The peak concentration was that measured in drug assays based on sampling immediately after the drug infusion. The relationship between drug exposure (AUC 0-24 /MIC or C max /MIC or fT .MIC or trough/MIC) and MAC microbial effect was modelled using the inhibitory sigmoid E max model. Four parameters were calculated: maximal kill or E max ; the concentration mediating 50% of E max or EC 50 ; the Hill slope (H); and the bacterial burden in non-treated HFS-MAC (E con ). The PK/PD exposure linked to microbial kill was identified as the exposure associated with the lowest AIC score. Next, the inhibitory sigmoid E max relationship was used to calculate the exposure associated with 80% of E max (EC 80 ), which was considered the exposure associated with optimal microbial kill. We also identified the exposure associated with bacteriostasis (i.e. which held the bacterial burden constant compared with day 0), as well as that associated with 1.0 log 10 cfu/mL kill compared with day 0, which was defined as indicating a bactericidal effect.
Monte Carlo simulations to identify optimal clinical doses for pulmonary MAC treatment
In order to translate our results to the clinic, we performed Monte Carlo simulations to identify the dose of linezolid that would lead to exposures that were: (i) bacteriostatic; (ii) the EC 80 ; and (iii) bactericidal. For the domain of input in subroutine PRIOR of ADAPT, we used the linezolid pharmacokinetic parameter estimates identified by Abe et al.
14 in 435 patients for a one-compartment model, for the average adult weight for the United States of 81.93 kg, which were a clearance of 6.0 L/h [inter-individual variability as %CV (IIV) " 46.6%], a volume of 54.53 L (IIV " 25.9%) and an absorption constant of 0.583 (we set an IIV " 40%). For intrapulmonary or ELF-to-serum AUC 0-24 penetration ratio, we used the value 3.29 identified by Conte et al. 6 Linezolid has a low protein binding of 31%; thus we ignored this protein binding. We simulated the input of doses of 600, 1200, 1800, 2400 and 3000 mg administered once a day, and generated clearances of 10000 patients for each dose, and Linezolid for pulmonary MAC JAC ii25 generated 10000 AUC 0-24 values. We then examined the probability of target attainment for the EC 80 and 1.0 log 10 cfu/mL kill at each MIC, from 0.0625 to 32 mg/L, based on the range of linezolid MICs generated by Zhang et al. 15 in the largest collection of pulmonary MAC isolates from 255 patients. We then calculated the cumulative fraction of response (CFR) by summing over this MIC range.
Software and hardware
Syringe pumps were programmed in Fortran. Pharmacokinetic analyses, exposure-effect analyses and Monte Carlo simulations were performed using ADAPT 5 software. 16 Output was exported to Excel files and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) for graphing. All software was implemented on Macintosh hardware.
Results
The MIC for the laboratory strain was 4.0 mg/L. The relationship between linezolid concentration and microbial kill in 12-well plates is shown in Figure 1 . In this assay, the day 14 cultures resulted in an E max of 1.04+0.0 log 10 cfu/mL and an EC 50 of 0.8+0.22 % MIC while the EC 80 was 1.33 % MIC (r 2 " 0.95). In HFS-MAC experiments, linezolid clearance was identified as 0.012+0.001 L/h and volume as 0.144+0.002 L. The pharmacokinetic model predicted concentrations versus those observed are shown in Figure 2 (a). The slope was 0.96+0.01 and thus very close to 1.0, indicating that there was negligible to no bias (r 2 " 0.99). The time-kill curves achieved by these concentrations in the HFS-MAC are shown in Figure 2(b) for the daily dosing scheme, and in Figure 2 (c) for the non-daily dosing scheme. The graphs show that the maximum kill below stasis was 0.61 log 10 cfu/mL on the daily dosing scheme, on day 5, but was 1.07 log 10 cfu/mL based on an every-other-day dosing scheme, on day 3. The figures also show that after day 7, all regimens had failed.
Inhibitory sigmoid E max modelling revealed the AIC scores shown in Table 1 for each sampling day. Based on the lowest AIC scores the AUC 0-24 /MIC was chosen as the index most closely linked to microbial kill on any sampling day. Based on the pattern of microbial kill 
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ii26 shown in Figure 2 (b and c)-i.e. the highest depth of kill was on day 5 and that by day 7 all regimens had failed-and the fact that the lowest AIC score was on day 5, we used the day 5 inhibitory sigmoid E max relationship for further calculations. On day 5, the relative likelihood that the AUC 0-24 /MIC ratio was linked to microbial kill compared with peak/MIC was 1.64, but was 1176 compared with T .MIC and 893 compared with trough/MIC. The relationship between MAC burden and exposure on day 5, shown in Figure 3 The exposure associated with bacteriostasis was an AUC 0-24 /MIC of 7.82. The EC 80 was an AUC 0-24 /MIC ratio of 42.06. When day 7 inhibitory sigmoid E max relationships were used, the EC 80 did not change much, and was an AUC 0-24 /MIC ratio of 43.74. Thus, our optimal exposure estimates were robust. The AUC 0-24 /MIC associated with 1.0 log 10 cfu/mL kill (i.e. a bactericidal effect) was 40.63, not significantly different from the EC 80 . Thus, based on both the EC 80 and 1.0 log 10 kill, the target exposure associated with optimal microbial kill was chosen as 42.
Monte Carlo simulations of five daily linezolid doses in 10000 patients revealed a mean + SD clearance of 6.02+1.67 L/h, a volume of 54.50+3.79 L, and an absorption constant of 0.59+0.50 h
#1
; thus our simulations adequately recapitulated the original pharmacokinetics used in the input domain. The target attainment probability of each daily dose at each MIC for the bacteriostasis exposure are shown in Figure 4 . The cumulative fraction of response for bacteriostatic effect was 98.73% with the lowest dose of 600 mg/day, with the higher doses at 100%. As regards both the EC 80 target and 1.0 log 10 cfu/mL (bactericidal effect) exposure targets, Figure 5 (a) shows that because of the MICs, the target attainment probability with the standard 1200 mg/day dose fell below 90% at MICs .8 mg/L. This means that the susceptibility breakpoint above which patients fail linezolid therapy when treated for pulmonary MAC is 16 mg/L. Given the left skew of linezolid MICs in MAC, the MIC distribution means that 48.5% of isolates in the series we used would be considered resistant to linezolid at standard doses. Figure 5(b) , a nomogram of dose versus cumulative fraction of response, shows that the optimal dose to achieve EC 80 and bactericidal effect was 1800 mg/day.
Discussion
The current drugs used to treat MAC have poor kill rates, as indicated by the long duration of therapy, which often exceeds 1 year. This is consistent with the HFS-MAC ethambutol results, for which the maximal effect MAC burden was 0.62 log 10 cfu/mL higher than at the start of therapy. 3 The azithromycin maximal effect was better, but even then was only 0.6 log 10 cfu/mL below bacterial burden at start of therapy. 3, 4 Even then, the standard azithromycin dose would achieve the AUC 0-24 /MIC associated with that E max in 0% of patients, and indeed would achieve the exposure associated with bacteriostasis in only 7% of patients. 4 Macrolides and ethambutol constitute the backbone of the recommended therapeutic Figure 3 . Linezolid exposure-effect in the hollow-fibre system model of pulmonary MAC. The curves are shown for each sampling day up to day 10, and demonstrate that regrowth occurred by day 7. Since day 5 had the lowest Akaike Information Criterion score, we utilized the relationship on day 5 for calculating the optimal exposure. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Linezolid for pulmonary MAC JAC ii27 regimen for pulmonary MAC, and thus it is not a surprise that this regimen has a microbial success rate of only 22% in patients with therapy duration of .1 year. 2 Here, we show that linezolid achieved at least 1.0 log 10 cfu/mL kill in the same model within a few days, and is thus bactericidal. This drug and its congeners give us a better possibility of constructing a shorter-duration therapy regimen than the current regimen.
Here we identified the AUC 0-24 /MIC ratio as the PK/PD index that best explains the microbial effect of linezolid on intracellular MAC. This finding is similar to that of our published and unpublished results with linezolid in the hollow-fibre model of TB, for sutezolid and linezolid in the murine model of TB, linezolid in the hollow-fibre model of paediatric TB, and for the sterilizing effect. 7, 17 In the accompanying follow-up study, the linezolid congener tedizolid also demonstrated AUC/MIC-linked efficacy in the HFS-MAC. 18 Thus, the totality of evidence supports an AUC 0-24 /MIC link for oxazolidinone effect against slow-growing mycobacteria. This means that the dosing interval of these drugs (twice a day versus combining the whole dose once a day) will not matter as far as efficacy is concerned.
Thirdly, we identifed a linezolid AUC 0-24 /MIC of 7.8 as being associated with bacteriostasis. Monte Carlo simulations demonstrated that even a dose of 600 mg/day would achieve this, which is better than we have identified with clinical doses of azithromycin, for example. 4 We identified a linezolid AUC 0-24 /MIC of 42.1 as being associated with a bactericidal effect. Monte Carlo simulations revealed that the standard dose of 1200 mg/day would achieve that exposure in only 71% of patients, and that the optimal dose is 1800 mg/day. These doses are likely to be in the range associated with a high rate of adverse events; in the case of TB, the 1200 mg standard dose was associated with severe adverse events in about 80% of patients.
Finally, we propose a MAC linezolid susceptibility breakpoint of 16 mg/L for delineating which patients would fail therapy and which ones will succeed, based on the standard dose. Current MIC breakpoints are set at MIC !32 mg/L for resistance. [19] [20] [21] In Figure 5 (a) we show that at MICs !32 mg/L, even the standard 1200 mg/day dose achieves optimal microbial kill in 0% of patients. Unfortunately, at our proposed breakpoint, about 50% of clinical isolates would be resistant to begin with. Indeed, if one used the MIC distribution of MAC isolates in American patients published by Brown-Elliott et al., 19 which had an even higher left skew, 80% of clinical isolates would be considered linezolid resistant at a breakpoint of 16 mg/L. While that is not good, it is nevertheless better than macrolides at standard dose. 4, 22 There are some limitations to our study. First, our assays failed to capture the linezolid-resistant subpopulation. This is likely due to the limitation of our assay, which used the MIC value as the threshold to detect resistance. Second, we used a single strain of MAC three times throughout the study. Examination of more strains would be better. However, our Monte Carlo simulations took into account the MIC distribution of more than 200 clinical isolates. Thus, the shortage of strains could be partially offset by the Monte Carlo experiments. Third, in our simulations we did not take into account protein binding. Linezolid is only 31% protein bound. However, if we had taken this into account, the doses associated with optimal bactericidal effect would have been even higher in the toxicity range than what we found.
In summary, we have identified the PK/PD parameter associated with efficacy for linezolid and the exposure related to optimal kill. In addition, we have identified a susceptibility breakpoint for linezolid at the current standard dose above which patients are likely to fail therapy with linezolid when treated for pulmonary MAC. A linezolid MIC of 16 mg/L was identified. Cumulative fraction of response for bactericidal effect with various doses of linezolid, which demonstrates that only a dose of 1800 mg or greater would be able achieve the exposure that mediates 1.0 log 10 cfu/mL kill in .90% of patients. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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